Concepts (85)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 5 | 2026 | 312 | 2.040 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2025 | 50 | 0.990 |
Why?
|
| Reed-Sternberg Cells | 1 | 2026 | 19 | 0.970 |
Why?
|
| Cellular Senescence | 1 | 2026 | 221 | 0.840 |
Why?
|
| Immunoconjugates | 1 | 2023 | 49 | 0.770 |
Why?
|
| Telomere Shortening | 1 | 2019 | 35 | 0.590 |
Why?
|
| Cell Differentiation | 1 | 2026 | 1947 | 0.570 |
Why?
|
| Telomerase | 1 | 2019 | 157 | 0.560 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 137 | 0.540 |
Why?
|
| Neutropenia | 1 | 2019 | 205 | 0.530 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 1356 | 0.460 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 1810 | 0.400 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2024 | 231 | 0.340 |
Why?
|
| Radiation Pneumonitis | 2 | 2022 | 11 | 0.330 |
Why?
|
| Cancer Survivors | 2 | 2022 | 268 | 0.260 |
Why?
|
| Adolescent | 11 | 2025 | 20982 | 0.240 |
Why?
|
| Child | 11 | 2026 | 26299 | 0.230 |
Why?
|
| Mutation | 1 | 2019 | 6177 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 173 | 0.200 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 134 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2025 | 617 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 1 | 2025 | 387 | 0.190 |
Why?
|
| MAP Kinase Signaling System | 1 | 2024 | 305 | 0.190 |
Why?
|
| Translocation, Genetic | 1 | 2024 | 350 | 0.180 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 164 | 0.180 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2022 | 140 | 0.160 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2021 | 218 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1277 | 0.160 |
Why?
|
| Lymphoma, B-Cell | 1 | 2021 | 149 | 0.150 |
Why?
|
| Child, Preschool | 6 | 2026 | 15057 | 0.150 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 159 | 0.150 |
Why?
|
| Apoptosis | 1 | 2026 | 1861 | 0.150 |
Why?
|
| Transcriptome | 1 | 2026 | 1163 | 0.150 |
Why?
|
| Gene Expression Profiling | 1 | 2026 | 1833 | 0.150 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 207 | 0.140 |
Why?
|
| Humans | 15 | 2026 | 131680 | 0.140 |
Why?
|
| Survivors | 1 | 2020 | 354 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 143 | 0.130 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 55 | 0.130 |
Why?
|
| Sepsis | 1 | 2021 | 501 | 0.130 |
Why?
|
| Lung | 2 | 2022 | 1565 | 0.120 |
Why?
|
| Recurrence | 3 | 2025 | 1483 | 0.120 |
Why?
|
| Adult | 5 | 2025 | 31719 | 0.110 |
Why?
|
| Incidence | 2 | 2020 | 3347 | 0.110 |
Why?
|
| Stroke | 1 | 2022 | 1049 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 3101 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 5297 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2024 | 220 | 0.090 |
Why?
|
| Female | 8 | 2025 | 71186 | 0.090 |
Why?
|
| Young Adult | 5 | 2025 | 10104 | 0.090 |
Why?
|
| Radiotherapy Dosage | 2 | 2022 | 215 | 0.080 |
Why?
|
| Male | 8 | 2025 | 65267 | 0.080 |
Why?
|
| Prognosis | 1 | 2019 | 4952 | 0.080 |
Why?
|
| Risk Factors | 2 | 2020 | 10959 | 0.070 |
Why?
|
| Neoplasms | 2 | 2022 | 2969 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 1911 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2025 | 12984 | 0.050 |
Why?
|
| Adenine Nucleotides | 1 | 2024 | 37 | 0.050 |
Why?
|
| Arabinonucleosides | 1 | 2024 | 34 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2024 | 79 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2024 | 96 | 0.050 |
Why?
|
| Infant | 3 | 2024 | 13306 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2024 | 178 | 0.050 |
Why?
|
| Organs at Risk | 1 | 2022 | 40 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2022 | 220 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 179 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 182 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 209 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 286 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2021 | 286 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 542 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 646 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 210 | 0.030 |
Why?
|
| Bleomycin | 1 | 2018 | 111 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 837 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 155 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 910 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2024 | 1617 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1405 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1099 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2025 | 17667 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 1625 | 0.020 |
Why?
|
| Middle Aged | 2 | 2024 | 28889 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2120 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 21261 | 0.010 |
Why?
|